Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Takeda Shaves Off European Subsidiaries And U.S. Jobs On Japanese Approval Day

This article was originally published in PharmAsia News

Executive Summary

Daiichi Sankyo's Denosumab and Bayer's Xarelto will soon make their appearance in the Japanese market.

You may also be interested in...

AstraZeneca's Nexium, J&J's Simponi Lead Charge Of New Products To Receive Reimbursement Prices In Japan

TOKYO - A new round of drugs were cleared for market launch in Japan after the latest round of National Health Insurance price listings, and AstraZeneca PLC's blockbuster Nexium (esomeprazole), waning in the West but picking up speed in Asian markets, leads the new wave of products

Results For Bayer's Xarelto In Japanese Phase III Trial In Line With Expectations

TOKYO - Bayer AG's anticoagulant Xarelto (rivaroxaban) met its primary endpoint of clinically relevant bleeding - major and non-major bleeding - in a Japanese Phase III trial, in line with the drug's performance in a 14,000+ global Phase III study, easing the path for approval in Japan

FCPA In The China Framework Warrants Special Attention

The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts